Baidu
map

IgG4相关性疾病临床表现多样,谨防误诊

2018-10-24 吉晓菲 检验医学

2018年5月11日,《关于公布第一批罕见病目录的通知》公布,IgG4相关性疾病名列其中。那么何为IgG4相关性疾病?IgG4相关性疾病相关性疾病为何逐渐得到了国际社会的关注和重视?

2018年5月11日,《关于公布第一批罕见病目录的通知》公布,IgG4相关性疾病名列其中。那么何为IgG4相关性疾病?IgG4相关性疾病相关性疾病为何逐渐得到了国际社会的关注和重视?

首先应该知道,根据抗原的性质,人类体内针对抗原的IgG抗体通常呈现不同的亚型倾向性,IgG亚类包括IgG1、IgG2、IgG3、IgG4四类,其血清浓度分别为:4.9~11.4g/L,占43%~75%;1.5~6.4g/L,占16%~ 48%;0.11~0.85g/L,占1.7%~7.5%;0.03~ 2.0g/L,占0.8%~11.7%。其中IgG1、IgG3是针对蛋白抗原产生,IgG2针对糖类抗原,而IgG4是抗原反复刺激产生的。

IgG4相关性疾病的历史认知

1960
首次报道了一例慢性炎症硬化性胰腺炎患者

1995
首次提出自身免疫性胰
腺炎概念

2001
发现自身免疫胰腺炎所累及的多个脏器的免疫组织化学均显示大量的IgG4阳性浆细胞浸润

2003
首次提出IgG4相关性
疾病的概念

2010
AutoimmuneRev杂志上正式宣布该种疾病的诞生

因此,IgG4相关性疾病是一种与IgG4相关的疾病,是近年来新认识的一种由免疫介导的慢性炎症伴纤维化的疾病。累及多器官或组织;受累器官或组织肿胀伴硬化;血清IgG4水平增高;组织中淋巴细胞和IgG4阳性浆细胞浸润。

它是系统性的自身免疫性疾病,通常累及胰腺,经常涉及其他组织,因此诊断通常需要结合临床表现(腹痛、体重减轻、黄疸)、血清学(血清IgG4浓度升高)、影像学(胰腺弥散性增生,可能发现类似于肿瘤的局部肿胀)、组织学(IgG4阳性细胞浸润,出现纤维变性)。

2011年IgG4相关性疾病诊断标准

(1)临床检查显示1个或多个器官特征性的弥漫性/局限性肿大或肿块形成;

(2)血液学检查显示血清IgG4升高>>1350mgdL;

(3)组织学检查显示:

   ①大量淋巴细胞和浆细胞浸润,伴纤维化;
   ②组织中浸润的IgG4+浆细胞与浆细胞的比值>40%,且每高倍镜视野下IgG4+浆细胞>10个。

临床上IgG4相关性疾病误诊的病例很多

病例1(IgG4相关硬化性胆管炎误诊为胆管肿瘤)

患者,男,60岁。因“部不适1月,乏力、尿黄半月余”。查ALT:125U/L,AST:55U/L, 总胆红素(TBil):4.8μmol/L, 白蛋白(Alb):46g/L, 口服护肝片后效果不佳。

10天后查 ALT:157U/L, AST:119U/L, TBil:118.2μmol/L, DBil:69.9μmol/L, GGT:656U/L, ALP:586U/L, 脂肪酶:1137U/L,淀粉酶正常;

乙肝抗原抗体: HBsAg(-) 、HBsAb(+) 、HBeAg(-) 、HBeAb(+) 、HBcAb(+) , 丙型肝炎抗体阴性。

腹部磁共振、磁共振胰胆道成像(MRCP)结果:胰腺炎,胆总管下段及胰头部胰管管壁增厚强化伴胆系扩张,考虑炎症所致可能性大。

内镜下逆行胰胆管造影术(ERCP):黏膜组织慢性炎伴糜烂,纤维肉芽组织增生,间质见部分嗜酸粒细胞浸润。再次行ERCP,黏膜组织慢性炎,并伴糜烂,部分腺上皮呈中度不典型增生,建议治疗后复查。以“梗阻性黄疸:胆管癌?”入院。

入院后腹部增强磁共振:考虑炎性病变可能性大,穿刺活检除外肿瘤性病变;胰腺形态饱满,不除外胰腺炎(IgG相关性)可能,结合临床。进一步查IgG亚型,IgG4:1690.0mg/dl, 结合病史查体及化验检查结果,诊断“IgG4相关硬化性胆管炎”。

病例2(以尿频为首发表现的IgG4相关性疾病):

患者,男,65岁,因“尿频5个月,双颌下腺肿伴乏力3个月,加重10余天”入院。患者5个月前无明显诱因出现尿频、尿失禁,尤以夜尿增多明显,行前列腺彩超、PSA等检查未发现明显异常,后口服“卫喜康”治疗,尿失禁症状好转,但仍有尿频。

辅助检查

? 免疫球蛋白G4:78.700g/L
? 免疫球蛋白G:117g/L
? C3:0.21g/L
? C4:0.02g/L
? 球蛋白:54.7g/L
? CRP:9.17mg/L
? 血沉:120mm/1h
? 血清游离λ链:235.00mg/L
? 血清游离κ链:306.00mg/L
? 24h尿LAM轻链:79.60mg/24h
? 24h尿KAP轻链:404.00mg/24h
? 24h尿微量白蛋白:29.60mg/24h
? 24h尿蛋白定量:0.56g/24h
? ANA、抗线粒体M2全阴性
? 免疫组化结果:CD138(+) , CD34 (血管内皮+), IgG4蛋白(+), IgG蛋白(+), CD10 (散在+), CD7 (上皮+), LCA (+) , CD20 (灶状+), CD3 (+)
? 骨髓涂片、活检、染色体未见明显异常

结合病史及辅助检查诊断为IgG4相关性疾病、2型糖尿病、主动脉瓣瓣膜置换术后。给予激素加免疫抑制剂、降糖、抗凝等对症支持治疗,患者尿频、乏力、口干等症状好转,血清IgG4水平较前明显下降、颌下腺肿大较前明显消退后出院,目前随访中。

IgG4相关性疾病实验室检查:嗜酸性粒细胞↑;血沉↑;CRP↑;血清IgG↑;血清IgG4↑(>135mg/dl);血清总IgE↑;自身抗体大多数阴性;低补体。

总之,IgG4的血清学检测对于IgG4相关性疾病的诊断非常重要;IgG4越高,患者发生其他器官受累的可能性越高;IgG4具有高度的敏感性和特异性,但是不能作为诊断的单独依据;激素治疗过程中,IgG4水平的上升,和治疗后IgG4水平上升,提示有复发风险,建议每隔半年进行复查。IgG4相关性疾病不是常见病,应先排除其它疾病后再考虑。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837583, encodeId=b698183e58310, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Mar 18 23:06:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350149, encodeId=9c731350149ed, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482966, encodeId=ed0914829669c, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615191, encodeId=3fd316151912d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350413, encodeId=ac2035041365, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Oct 24 21:52:39 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837583, encodeId=b698183e58310, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Mar 18 23:06:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350149, encodeId=9c731350149ed, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482966, encodeId=ed0914829669c, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615191, encodeId=3fd316151912d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350413, encodeId=ac2035041365, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Oct 24 21:52:39 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837583, encodeId=b698183e58310, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Mar 18 23:06:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350149, encodeId=9c731350149ed, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482966, encodeId=ed0914829669c, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615191, encodeId=3fd316151912d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350413, encodeId=ac2035041365, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Oct 24 21:52:39 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837583, encodeId=b698183e58310, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Mar 18 23:06:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350149, encodeId=9c731350149ed, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482966, encodeId=ed0914829669c, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615191, encodeId=3fd316151912d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350413, encodeId=ac2035041365, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Oct 24 21:52:39 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837583, encodeId=b698183e58310, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Mar 18 23:06:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350149, encodeId=9c731350149ed, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482966, encodeId=ed0914829669c, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615191, encodeId=3fd316151912d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Fri Oct 26 10:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350413, encodeId=ac2035041365, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Oct 24 21:52:39 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

“IgG4相关疾病”得到明确——它让一些“癌症病人”得到昭雪

医学无止境,不时会有一些非常疑难的疾病展现在医生面前。难到什么程度?“无名氏”疾病!医生没有办法下诊断,“喊”不出其名字,是因为这个疾病还没有被命名。

解读《IgG4相关性疾病管理和治疗的国际共识指南》

2015年3月,Arthritis&Rheumatology杂志发表了《IgG4相关性疾病管理和治疗的国际共识指南》,以下简称指南。该指南是迄今为止国际上关于IgG4相关性疾病(IgG4-relateddisease,IgG4-RD)诊治和管理的首个指导性意见,对指导IgG4-RD的临床实践有重要意义。 指南制定背景 IgG4-RD是一种免疫介导的炎症伴纤维化疾病,可影响多个器官,

Baidu
map
Baidu
map
Baidu
map